JP2009506066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506066A5 JP2009506066A5 JP2008528168A JP2008528168A JP2009506066A5 JP 2009506066 A5 JP2009506066 A5 JP 2009506066A5 JP 2008528168 A JP2008528168 A JP 2008528168A JP 2008528168 A JP2008528168 A JP 2008528168A JP 2009506066 A5 JP2009506066 A5 JP 2009506066A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- unsaturated
- aromatic
- group
- saturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 120
- 229920006395 saturated elastomer Polymers 0.000 claims 106
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 claims 103
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 86
- 125000003118 aryl group Chemical group 0.000 claims 81
- 229910052760 oxygen Inorganic materials 0.000 claims 70
- 229910052757 nitrogen Inorganic materials 0.000 claims 66
- 239000001301 oxygen Substances 0.000 claims 63
- 229910052717 sulfur Inorganic materials 0.000 claims 63
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 62
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 57
- 239000011593 sulfur Substances 0.000 claims 56
- 150000001875 compounds Chemical class 0.000 claims 55
- 125000005842 heteroatom Chemical group 0.000 claims 54
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 32
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 27
- 125000000304 alkynyl group Chemical group 0.000 claims 27
- 150000002148 esters Chemical class 0.000 claims 27
- 239000000651 prodrug Substances 0.000 claims 27
- 229940002612 prodrug Drugs 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 24
- 125000004429 atom Chemical group 0.000 claims 24
- 229910052799 carbon Inorganic materials 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 125000003342 alkenyl group Chemical group 0.000 claims 20
- 150000001204 N-oxides Chemical class 0.000 claims 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000002252 acyl group Chemical group 0.000 claims 11
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 229910052794 bromium Inorganic materials 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 229910052740 iodine Inorganic materials 0.000 claims 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000001336 alkenes Chemical class 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- 125000005841 biaryl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 108020004485 Nonsense Codon Proteins 0.000 claims 2
- 206010062255 Soft tissue infection Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 150000002016 disaccharides Chemical class 0.000 claims 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 2
- 150000002118 epoxides Chemical class 0.000 claims 2
- 150000002337 glycosamines Chemical class 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000037434 nonsense mutation Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 206010040872 skin infection Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000037041 Community-Acquired Infections Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- GDIHDSKOVXEJQQ-UHFFFAOYSA-N NC(O)=O.NC(O)=O.NC(O)=O.N Chemical compound NC(O)=O.NC(O)=O.NC(O)=O.N GDIHDSKOVXEJQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910021386 carbon form Inorganic materials 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 CC(*)(*)N[C@@](*)(CN(C)C12)[C@]1(*)[C@@](*)(C(*)SC)OC2(I)I Chemical compound CC(*)(*)N[C@@](*)(CN(C)C12)[C@]1(*)[C@@](*)(C(*)SC)OC2(I)I 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71144305P | 2005-08-24 | 2005-08-24 | |
| US76290706P | 2006-01-26 | 2006-01-26 | |
| PCT/US2006/033170 WO2007025098A2 (en) | 2005-08-24 | 2006-08-24 | Triazole compounds and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009506066A JP2009506066A (ja) | 2009-02-12 |
| JP2009506066A5 true JP2009506066A5 (https=) | 2009-10-08 |
Family
ID=37467427
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008528247A Expired - Fee Related JP5395432B2 (ja) | 2005-08-24 | 2006-08-24 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
| JP2008528168A Withdrawn JP2009506066A (ja) | 2005-08-24 | 2006-08-24 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
| JP2013169594A Expired - Fee Related JP5981401B2 (ja) | 2005-08-24 | 2013-08-19 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
| JP2015223733A Pending JP2016094421A (ja) | 2005-08-24 | 2015-11-16 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
| JP2017141745A Pending JP2018008970A (ja) | 2005-08-24 | 2017-07-21 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
| JP2018169395A Pending JP2019023194A (ja) | 2005-08-24 | 2018-09-11 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008528247A Expired - Fee Related JP5395432B2 (ja) | 2005-08-24 | 2006-08-24 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013169594A Expired - Fee Related JP5981401B2 (ja) | 2005-08-24 | 2013-08-19 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
| JP2015223733A Pending JP2016094421A (ja) | 2005-08-24 | 2015-11-16 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
| JP2017141745A Pending JP2018008970A (ja) | 2005-08-24 | 2017-07-21 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
| JP2018169395A Pending JP2019023194A (ja) | 2005-08-24 | 2018-09-11 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US8278281B2 (https=) |
| EP (3) | EP3290427A1 (https=) |
| JP (6) | JP5395432B2 (https=) |
| DK (1) | DK1934238T3 (https=) |
| ES (1) | ES2638427T3 (https=) |
| HR (1) | HRP20171285T1 (https=) |
| WO (2) | WO2007025284A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1723159B1 (en) | 2004-02-27 | 2019-06-12 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
| EP1934237A2 (en) | 2005-08-24 | 2008-06-25 | Rib-X Pharmaceuticals, Inc. | Triazole compounds and methods of making and using the same |
| EP3290427A1 (en) * | 2005-08-24 | 2018-03-07 | Melinta Therapeutics, Inc. | Triazole compounds and methods of making and using the same |
| WO2008106204A1 (en) * | 2007-02-28 | 2008-09-04 | Rib-X-Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| BRPI0823405A2 (pt) * | 2007-07-06 | 2012-12-25 | Paratek Pharmaceuticals, Inc. | mÉtodos para sintetizar compostos de tetraciclina substituÍda |
| JP2011026260A (ja) * | 2009-07-28 | 2011-02-10 | Central Glass Co Ltd | ３位に脱離基を有する２−フルオロプロピルアミン保護体または該アミンｎ−アルキル保護体 |
| CN101619085B (zh) * | 2009-08-11 | 2015-04-22 | 沈阳药科大学 | 红霉素衍生物及其作为肿瘤细胞增殖抑制剂的用途 |
| AR092278A1 (es) * | 2012-08-31 | 2015-04-08 | Novartis Ag | Proceso de obtencion de derivados n-acilicos de bifenil-alanina e intermediarios relacionados |
| CN107205989A (zh) | 2014-11-14 | 2017-09-26 | 梅琳塔治疗公司 | 治疗、预防或降低皮肤感染风险的方法 |
| WO2018191682A1 (en) * | 2017-04-15 | 2018-10-18 | Melinta Therapeutics, Inc. | Triazole compounds and methods of making and using the same |
| CN110108826A (zh) * | 2019-05-24 | 2019-08-09 | 内蒙古蒙牛乳业（集团）股份有限公司 | 乳或乳制品中氟苯尼考胺的检测方法 |
| US20210371389A1 (en) * | 2020-04-24 | 2021-12-02 | Kansas Soybean Commission | One-step synthesis of soybean polyols |
| US20240076293A1 (en) * | 2020-12-28 | 2024-03-07 | Georgia Tech Research Corporation | Compositions and Methods for Inhibiting Fibrosis, Inflammation and Cancer |
| CN115745823B (zh) * | 2022-11-03 | 2024-02-23 | 武夷学院 | 一种化合物的制备方法及其应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3725385A (en) | 1970-11-02 | 1973-04-03 | Abbott Lab | Process for the demethylation of 3-amino macrolides |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| MY113693A (en) | 1992-05-26 | 2002-05-31 | Chugai Pharmaceutical Co Ltd | Erythromycin derivatives having an enterokinesis stimulating action |
| US6927057B2 (en) | 1993-09-20 | 2005-08-09 | Kosan Biosciences | Macrolide analogs |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| DE19604223A1 (de) * | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
| BR9812577A (pt) | 1997-09-30 | 2000-10-17 | Abbott Lab | Composto, processo para preparar o mesmo, composição farmacêutica, e, processo para tratar infecções bacterianas |
| US6124269A (en) | 1997-10-29 | 2000-09-26 | Abbott Laboratories | 2-Halo-6-O-substituted ketolide derivatives |
| AR043071A1 (es) | 1997-10-31 | 2005-07-20 | Abbott Lab | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica |
| US6288234B1 (en) | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| IT1301968B1 (it) | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| GB9821938D0 (en) | 1998-10-09 | 1998-12-02 | Zeneca Ltd | Chemical compounds |
| HRP980646B1 (en) | 1998-12-30 | 2008-02-29 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | Novel oleandomycin derivatives |
| US6939861B2 (en) | 1999-04-16 | 2005-09-06 | Kosan Biosciences, Inc. | Amido macrolides |
| US6451768B1 (en) | 1999-04-16 | 2002-09-17 | Kosan Biosciences, Inc. | Macrolide antiinfective agents |
| US6514944B2 (en) | 1999-04-16 | 2003-02-04 | Kosan Biosciences, Inc. | Macrolide antiinfective agents |
| US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
| EP1101769A3 (en) | 1999-11-18 | 2001-10-24 | Pfizer Products Inc. | Nitrogen containing erythromycin derivatives |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| KR20020072311A (ko) | 2000-02-10 | 2002-09-14 | 파마시아 앤드 업존 캄파니 | 피페라진 아미드 치환기를 갖는 옥사졸리디논 티오아미드 |
| WO2001060833A2 (en) | 2000-02-18 | 2001-08-23 | Kosan Biosciences, Inc. | Motilide compounds |
| GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
| ATE321770T1 (de) | 2000-08-17 | 2006-04-15 | Kitasato Inst | Pseudoerythromycin-derivate |
| JP4162992B2 (ja) | 2000-08-22 | 2008-10-08 | バジリア ファルマスーチカ アーゲー | 抗菌活性を有する新規マクロライド |
| CA2429709A1 (en) | 2000-12-01 | 2002-07-04 | Gary Ashley | Motilide compounds |
| CA2451391A1 (en) | 2001-07-03 | 2003-01-16 | Chiron Corporation | C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| SI1427711T1 (sl) | 2001-09-11 | 2005-12-31 | Astrazeneca Ab | Oksazolidinonski in/ali izoksazolinski derivati kot antibakterijska sredstva |
| EP1443930A1 (en) | 2001-10-25 | 2004-08-11 | AstraZeneca AB | Isoxazoline derivatives useful as antimicrobials |
| JP2005538927A (ja) | 2002-01-17 | 2005-12-22 | コーザン バイオサイエンシス インコーポレイテッド | アミドマクロライド |
| US8063021B2 (en) | 2002-01-17 | 2011-11-22 | Kosan Biosciences Incorporated | Ketolide anti-infective compounds |
| US6992069B2 (en) | 2002-04-30 | 2006-01-31 | Yu-Gui Gu | Tricyclic macrolide antibacterial compounds |
| US20050045585A1 (en) * | 2002-05-07 | 2005-03-03 | Gang Zhang | Method of electrochemically fabricating multilayer structures having improved interlayer adhesion |
| JP4638225B2 (ja) * | 2002-05-30 | 2011-02-23 | ザ スクリプス リサーチ インスティテュート | 銅を触媒とするアジドとアセチレンのライゲーション |
| ITMI20021726A1 (it) * | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| TW200420573A (en) | 2002-09-26 | 2004-10-16 | Rib X Pharmaceuticals Inc | Bifunctional heterocyclic compounds and methods of making and using same |
| AU2004217919A1 (en) | 2003-03-05 | 2004-09-16 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using the same |
| JPWO2004078771A1 (ja) | 2003-03-07 | 2006-06-08 | 大正製薬株式会社 | ２−フルオロ−６−ｏ−置換ケトライド誘導体 |
| EP1638549A4 (en) | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
| CA2523134A1 (en) | 2003-04-25 | 2004-11-11 | Chiron Corporation | Pyridyl substituted ketolide antibiotics |
| US7163924B2 (en) | 2003-04-25 | 2007-01-16 | Chiron Corporation | Ketolide derivatives |
| EP1656370B1 (en) * | 2003-06-03 | 2012-08-15 | Rib-X Pharmaceuticals, Inc. | Biaryl heterocyclic compounds and methods of making and using the same |
| WO2005042554A1 (en) | 2003-10-30 | 2005-05-12 | Rib-X Pharmaceuticals, Inc. | Bifunctional macrolide heterocyclic compounds and methods of making and using the same |
| US20070270357A1 (en) | 2003-11-18 | 2007-11-22 | Farmer Jay J | Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same |
| AU2003304705A1 (en) | 2003-12-24 | 2005-08-03 | Enanta Pharmaceuticals, Inc. | 11-csubsituted erythromycin derivatives |
| EP1723159B1 (en) * | 2004-02-27 | 2019-06-12 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
| WO2005118610A2 (en) | 2004-06-01 | 2005-12-15 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
| US7402568B2 (en) | 2004-09-29 | 2008-07-22 | Enanta Pharmaceuticals, Inc. | Bicyclic 9a-azalide derivatives |
| US7419962B2 (en) | 2004-12-07 | 2008-09-02 | Enanta Pharmaceuticals, Inc. | 3,6-bicyclolides |
| US7229972B2 (en) | 2004-12-07 | 2007-06-12 | Enanta Pharmaceuticals, Inc. | 3,6-Bicyclolides |
| WO2006065743A2 (en) | 2004-12-13 | 2006-06-22 | Enanta Pharmaceuticals, Inc. | Tetracylic bicyclolides |
| UA85937C2 (uk) | 2004-12-21 | 2009-03-10 | Пфайзер Продактс Інк. | Макроліди |
| US7271155B2 (en) | 2005-01-07 | 2007-09-18 | Enanta Pharmaceuticals, Inc. | 9A, 11-2C-bicyclic 9a-azalide derivatives |
| EP3290427A1 (en) * | 2005-08-24 | 2018-03-07 | Melinta Therapeutics, Inc. | Triazole compounds and methods of making and using the same |
| EP1934237A2 (en) | 2005-08-24 | 2008-06-25 | Rib-X Pharmaceuticals, Inc. | Triazole compounds and methods of making and using the same |
-
2006
- 2006-08-24 EP EP17178221.2A patent/EP3290427A1/en not_active Withdrawn
- 2006-08-24 WO PCT/US2006/033645 patent/WO2007025284A1/en not_active Ceased
- 2006-08-24 JP JP2008528247A patent/JP5395432B2/ja not_active Expired - Fee Related
- 2006-08-24 EP EP06802533.7A patent/EP1934238B1/en not_active Not-in-force
- 2006-08-24 JP JP2008528168A patent/JP2009506066A/ja not_active Withdrawn
- 2006-08-24 EP EP06824847A patent/EP1928893A2/en not_active Withdrawn
- 2006-08-24 DK DK06802533.7T patent/DK1934238T3/en active
- 2006-08-24 HR HRP20171285TT patent/HRP20171285T1/hr unknown
- 2006-08-24 ES ES06802533T patent/ES2638427T3/es active Active
- 2006-08-24 US US11/990,883 patent/US8278281B2/en not_active Expired - Fee Related
- 2006-08-24 WO PCT/US2006/033170 patent/WO2007025098A2/en not_active Ceased
-
2012
- 2012-09-14 US US13/616,962 patent/US20130065845A1/en not_active Abandoned
-
2013
- 2013-08-19 JP JP2013169594A patent/JP5981401B2/ja not_active Expired - Fee Related
- 2013-08-21 US US13/972,732 patent/US9006189B2/en not_active Expired - Fee Related
-
2015
- 2015-03-18 US US14/661,863 patent/US20160031926A1/en not_active Abandoned
- 2015-11-16 JP JP2015223733A patent/JP2016094421A/ja active Pending
-
2017
- 2017-05-17 US US15/597,701 patent/US20180094016A1/en not_active Abandoned
- 2017-07-21 JP JP2017141745A patent/JP2018008970A/ja active Pending
-
2018
- 2018-09-11 JP JP2018169395A patent/JP2019023194A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009506066A5 (https=) | ||
| CA2566544C (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| US6245781B1 (en) | Method for suppressing allogenic immune response or prevention/treatment of graft vs. host disease or graft rejection | |
| JP2009506075A5 (https=) | ||
| AU2014208965B2 (en) | Compounds and methods for treating bacterial infections | |
| WO2016161361A4 (en) | Compositions and methods of targeting mutant k-ras | |
| JP2004500384A (ja) | アザライド系抗生物質組成物 | |
| JP2012506870A (ja) | 胃腸疾患を治療するための方法 | |
| CN1777424A (zh) | 抗肿瘤联合药物 | |
| JP2009506063A5 (https=) | ||
| RS52808B (sr) | Kinolinski derivati kao antibakterijski agensi | |
| CA2367319A1 (en) | Erythromycin derivatives | |
| WO2005007143A2 (en) | Use of makrolides and ketolides for the treatment of tuberculosis | |
| KR20150006080A (ko) | 항생제 내성 세균 감염의 치료 | |
| KR20110050623A (ko) | 항생제 | |
| CN115461353B (zh) | 免疫调节o-het/芳基氮环内酯 | |
| JP2007509980A5 (https=) | ||
| JP2000351794A (ja) | エリスロマイシン誘導体 | |
| CN105524132B (zh) | 含有喹啉取代基的红霉素a酮内酯类抗生素衍生物、其制备方法及应用 | |
| KR102488654B1 (ko) | 마크로코신 화합물을 포함하는 약학적 조성물 및 마크로코신 화합물의 제조방법 | |
| Zhong et al. | In vivo pharmacokinetic and pharmacodynamic profiles of orbifloxacin against Staphylococcus aureus in a neutropenic murine thigh infection model | |
| JP2007512256A5 (https=) | ||
| CN103709177B (zh) | 利福霉素类沃尼妙林杂合抗生素及其制备方法 | |
| Asif et al. | An overview on antitubercular activities of fluoroquinolones and other related analogues | |
| EP4342484A1 (en) | Pharmaceutical composition comprising macrocosine compound and method for preparing macrocosine compound |